4.4 Review

An Update on the Utility of Coronary Artery Calcium Scoring for Coronary Heart Disease and Cardiovascular Disease Risk Prediction

Journal

CURRENT ATHEROSCLEROSIS REPORTS
Volume 18, Issue 3, Pages -

Publisher

CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-016-0565-6

Keywords

Coronary artery calcium; Coronary heart disease; Cardiovascular disease; Risk assessment; Primary prevention; Statins

Funding

  1. NIH/NHLBI
  2. American Heart Association
  3. Aetna Foundation
  4. FDA
  5. Pfizer
  6. Novartis
  7. Aralez Pharmaceuticals
  8. Luitpold Pharmaceuticals
  9. ISIS Pharmaceuticals

Ask authors/readers for more resources

Estimating cardiovascular disease (CVD) risk is necessary for determining the potential net benefit of primary prevention pharmacotherapy. Risk estimation relying exclusively on traditional CVD risk factors may misclassify risk, resulting in both undertreatment and overtreatment. Coronary artery calcium (CAC) scoring personalizes risk prediction through direct visualization of calcified coronary atherosclerotic plaques and provides improved accuracy for coronary heart disease (CHD) or CVD risk estimation. In this review, we discuss the most recent studies on CAC, which unlike historical studies, focus sharply on clinical application. We describe the MESA CHD risk calculator, a recently developed CAC-based 10-year CHD risk estimator, which can help guide preventive therapy allocation by better identifying both high-and low-risk individuals. In closing, we discuss calcium density, regional distribution of CAC, and extra-coronary calcification, which represent the future of CAC and CVD risk assessment research and may lead to further improvements in risk prediction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available